These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 24875360

  • 1. Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction.
    Liu X, Xue R, Ji L, Zhang X, Wu J, Gu J, Zhou M, Chen S.
    Biochem Biophys Res Commun; 2014 Jul 18; 450(1):117-23. PubMed ID: 24875360
    [Abstract] [Full Text] [Related]

  • 2. Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide.
    Imai Y, Varela GM, Jackson MB, Graham MJ, Crooke RM, Ahima RS.
    Gastroenterology; 2007 May 18; 132(5):1947-54. PubMed ID: 17484887
    [Abstract] [Full Text] [Related]

  • 3. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
    Yao J, Zhou CS, Ma X, Fu BQ, Tao LS, Chen M, Xu YP.
    World J Gastroenterol; 2014 Oct 21; 20(39):14430-41. PubMed ID: 25339829
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
    Wu W, Zhu B, Peng X, Zhou M, Jia D, Gu J.
    Biochem Biophys Res Commun; 2014 Jan 03; 443(1):68-73. PubMed ID: 24269813
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice.
    Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I.
    Hepatology; 2009 Oct 03; 50(4):1094-104. PubMed ID: 19637282
    [Abstract] [Full Text] [Related]

  • 8. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez R, Vlasuk GP, Harnish DC.
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar 03; 296(3):G543-52. PubMed ID: 19136377
    [Abstract] [Full Text] [Related]

  • 9. Metformin prevents hepatic steatosis by regulating the expression of adipose differentiation-related protein.
    Liu F, Wang C, Zhang L, Xu Y, Jang L, Gu Y, Cao X, Zhao X, Ye J, Li Q.
    Int J Mol Med; 2014 Jan 03; 33(1):51-8. PubMed ID: 24253218
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
    Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, Cai J, Qi Y, Fang ZZ, Takahashi S, Tanaka N, Desai D, Amin SG, Albert I, Patterson AD, Gonzalez FJ.
    J Clin Invest; 2015 Jan 03; 125(1):386-402. PubMed ID: 25500885
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation.
    Meng Q, Duan XP, Wang CY, Liu ZH, Sun PY, Huo XK, Sun HJ, Peng JY, Liu KX.
    Acta Pharmacol Sin; 2017 Jan 03; 38(1):69-79. PubMed ID: 27773935
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.